nalists at the meeting turned to photograph each member as he or she voted.3 He questioned whether such coverage is in the best interests of the patient.
Most IRB meetings neither warrant nor receive the media attention devoted to the Loma Linda or Utah IRBs. Nevertheless, both cases point to a new challenge for IRB members: dealing with the media. IRB members will confront the conflict between media interest and the benefits of a confidential review. Such extraordinary cases raise an additional challenge. IRBs ordinarily review two principal documents-the research protocol and the informed consent document. In cases such as that of Baby Fae, however, the IRB also reviews confidential information about a specific patient. The review of this information raises an unusual but important problem: the IRB must be careful to avoid becoming a vehicle for the violation of patient privacy.
Especially when considering dramatic procedures such as xenografts, IRB members may be obliged to explain the ethical and scientific reasoning behind their decisions to the public. argue that the California statutes in particular, however, "appear" to exclude IRBs. In fact, these rules have not been subjected to any substantial litigation with respect to IRBs and the interpretation of the court could vary from jurisdiction to jurisdiction. Given this, IRB members can reasonably expect the sunshine laws to be applied to their meetings in certain situations.
William Ziprick, the attorney for Loma Linda, argued that California open government laws did not apply to Loma Linda since it is a private institution." Thus, without any controlling state law, Loma Linda was free to make its own policy. He explained that the hospital keeps IRB deliberations confidential so the Baby Fae documents were not released to the press for public consideration. Media scrutiny of IRBs, in addition to any benefit, may also be harmful to the public. Premature disclosure of research protocols, made possible through the presence of the media at IRB meetings, might lead to news that is misleading rather than informative. For example, the press might choose to focus on an investigator's optimistic statements about the chances of success of a given treatment modality and overlook "whatever caution may be contained in the wording of the research protocol" itself.14 This kind of sensationalism may ultimately work to the public's disadvantage. For this reason, many maintain that the public should learn of biomedical developments only after they have been reviewed in the scientific press. Alexander M. Capron, of the University of Southern California Law School, argues that "this method not only preserves the dignity of all involved-from scientists to patients-but also means that the public learns about genuine 'advances' rather than merely being titillated by bizarre cases of as-yet unproven import." 15 In many ways, the aggressive character of the American press is antithetical to the thoughtful analysis requisite for scientific (and bioethical) decisions. Speaking of the Baby Fae case, Keith Reemtsma, a transplant surgeon at Columbia University, argues:
Science and news are, in a sense, asymmetrical and sometimes antagonistic. News emphasizes the uniqueness, the immediacy, the human interest in a case such as this. Science emphasizes verification, controls, comparisons, and patterns. Such scientific studies may not be possible in time for the afternoon press conference, and the uncertainties that scientists express may be misinterpreted as a lack of candor.'16'P'0 The press will, by its very nature, tend to focus on the particular aspects of a story that are sensational. Uncontrolled media access might thus lead to a type of reporting detrimental to the interests of the public in general and the patient in particular, rather than to the instructive coverage envisioned by Nelkin. What this probably means in practical terms is that meetings could be closed when: (1) specific patients are discussed and confidential health or personal information is revealed; (2) potentially patentable products or techniques are discussed; or (3) potentially damaging statements are made in confidence about the abilities of a given investigator. Though these are broad categories, there is still much that would not be protected from disclosure, for example, a general discussion of the ethical and scientific basis of a protocol. IRBs devote many months of study to a protocol such as that involving Baby Fae even before the patient is known. If Loma Linda were a public institution, media access could not ordinarily have been limited until the IRB began to discuss a specific patient.
Limits to the
In the Baby Fae case, where one particular patient became the focus of the review, the most important reason to limit media access was concern about patient privacy. IRB meetings should not become a forum for the violation of patient rights to a confidential doctorpatient relationship. In this case, there were legal considerations as well. Ziprick explained that even if someone had challenged the Loma Linda Medical Center standing rule on the confidentiality of IRB meetings, concerns about Baby Fae's privacy would have allowed the hospital to withhold the information. The consent form signed by Baby Fae's parents prohibits the release of any information about the patient without their consent.19 The California Confidentiality of Medical Information Act prevents a hospital or physician from acting against the wishes of the patient or releasing information that might identify him.20 Similar laws in other states would allow an IRB to refuse access to information because it would compromise the rights of a patient.21
In sum, the timing of media scrutiny and the material examined are of critical importance both with respect to IRB function and patient confidentiality. If media interest is taken as a given, IRB chairmen and members must focus on making the difficult decision of what material truly deserves to be privileged in light of the legal standards. Willingly or not, IRB members may, on occasion, be cast in the role of "managers of biomedical news." Although from the vantage of IRB function this may-to some-seem to be a deplorable development, the media can in many situations establish access to IRB meetings and documents.
In the unusual cases where a specific patient is considered, the IRB meetings should be entirely closed, as allowed by law. Nevertheless, even in these cases the public need for general information should be met. IRBs should have a policy for dealing with the media. This makes legal and political sense. Lawyers, journalists, and IRB members have an important responsibility to establish responsible standards and methods for managing access to IRB discussions and documents. We believe, and interpret present laws to allow, that the media should have access to: (1) the scientific protocol; (2) the unsigned informed consent document; and (3) perhaps a one-page statement of the pros and cons guiding the IRB decision. This information should be released for public consumption.
The case of Baby Fae thus brings to the fore the inherent conflict between the workings of the media and the IRB's need to protect both the patient's privacy and the patient's right to a thorough and confidential review. 
